Table 1.
Overview on study cohorts and study information
| Variable | Full population | BIC-8 [2] | CHOPIN [6] | ProCore [3] | Diagnostic evaluationsa | Study from Wilhelminen Hospitala |
|---|---|---|---|---|---|---|
| Population (N, %) | 10,329 (100.0%) | 888 (100.0%) | 1927 (100.0%) | 2279 (100.0%) | 4078 (100.0%) | 1157 (100.0%) |
| hs-cTn (N, %) | 4597 (44.5%) | 881 (99.2%) | 0 (0.0%) | 1478 (64.9%) | 2238 (54.9%) | 0 (0.0%) |
| NSTEMI (N, %) | 976 (9.4%) | 11 (1.2%) | 116 (6.0%) | 77 (3.4%) | 619 (15.2%) | 153 (13.2%) |
| 30-day all-cause death (N, %) | 33 (0.3%) | 2 (0.2%) | 10 (0.5%) | 15 (0.7%) | 0 (0.0%) | 6 (0.5%) |
| 30-day all-cause death missing (N, %) | 4095 (39.6%) | 14 (1.6%) | 0 (0.0%) | 0 (0.0%) | 4078 (100.0%) | 3 (0.3%) |
| Sex male (N, %) | 5905 (57.2%) | 563 (63.4%) | 1082 (56.1%) | 1299 (57.0%) | 2290 (56.2%) | 671 (58.0%) |
| Sex male missing (N, %) | 15 (0.1%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 15 (0.4%) | 0 (0.0%) |
| GRACE < 109 (N, %) | 6442 (62.4%) | 738 (83.1%) | 1454 (75.5%) | 1410 (61.9%) | 2049 (50.2%) | 791 (68.4%) |
| GRACE 109–140 (N, %) | 2307 (22.3%) | 123 (13.9%) | 374 (19.4%) | 437 (19.2%) | 1128 (27.7%) | 245 (21.2%) |
| GRACE > 140 (N, %) | 1310 (12.7%) | 13 (1.5%) | 99 (5.1%) | 176 (7.7%) | 901 (22.1%) | 121 (10.5%) |
| GRACE missing (N, %) | 270 (2.6%) | 14 (1.6%) | 0 (0.0%) | 256 (11.2%) | 0 (0.0%) | 0 (0.0%) |
| Time since symptom onset < 3 h (N, %) | 3855 (37.3%) | 239 (26.9%) | 1449 (75.2%) | 551 (24.2%) | 1257 (30.8%) | 359 (31.0%) |
| Time since symptom onset > 3 h (N, %) | 5604 (54.3%) | 496 (55.9%) | 463 (24.0%) | 1556 (68.2%) | 2362 (57.9%) | 727 (62.8%) |
| Time since symptom onset missing (N, %) | 870 (8.4%) | 153 (17.2%) | 15 (0.8%) | 172 (7.5%) | 459 (11.3%) | 71 (6.1%) |
| Age (mean, SD) (N, %) | 60.6 (17.5) | 54.1 (15.6) | 56.3 (12.8) | 57.8 (17.6) | 65.2 (18.6) | 61.4 (16.8) |
| Age missing (N, %) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| eGFR (mean, SD) (N, %) | 90.1 (21.9) | 96.9 (16.6) | 87.1 (21.2) | 93 (21.7) | - | 84.7 (24.6) |
| eGFR missing (N, %) | 4265 (41.3%) | 101 (11.4%) | 42 (2.2%) | 21 (0.9%) | 4078 (100.0%) | 23 (2.0%) |
| Diabetes mellitus (N, %) | 2123 (20.6%) | 121 (13.6%) | 554 (28.7%) | 344 (15.1%) | 909 (22.3%) | 195 (16.9%) |
| Diabetes mellitus missing (N, %) | 290 (2.8%) | 0 (0.0%) | 8 (0.4%) | 0 (0.0%) | 222 (5.4%) | 60 (5.2%) |
| Smoker (N, %) | 3117 (30.2%) | 289 (32.5%) | 635 (33.0%) | 622 (27.3%) | 1187 (29.1%) | 384 (33.2%) |
| Smoker missing (N, %) | 701 (6.8%) | 23 (2.6%) | 1 (0.1%) | 0 (0.0%) | 511 (12.5%) | 166 (14.3%) |
| CAD history (N, %) | 3491 (33.8%) | 229 (25.8%) | 726 (37.7%) | 654 (28.7%) | 1511 (37.1%) | 371 (32.1%) |
| CAD history missing (N, %) | 343 (3.3%) | 18 (2.0%) | 39 (2.0%) | 49 (2.2%) | 211 (5.2%) | 26 (2.2%) |
| CAD family history (N, %) | 2369 (22.9%) | 224 (25.2%) | 666 (34.6%) | 472 (20.7%) | 844 (20.7%) | 163 (14.1%) |
| CAD family history missing (N, %) | 3058 (29.6%) | 61 (6.9%) | 449 (23.3%) | 822 (36.1%) | 1219 (29.9%) | 507 (43.8%) |
| Hypertension (N, %) | 6645 (64.3%) | 513 (57.8%) | 1344 (69.7%) | 1180 (51.8%) | 2885 (70.7%) | 723 (62.5%) |
| Hypertension missing (N, %) | 327 (3.2%) | 11 (1.2%) | 11 (0.6%) | 84 (3.7%) | 184 (4.5%) | 37 (3.2%) |
| Hypercholesterolemia (N, %) | 4518 (43.7%) | 386 (43.5%) | 1042 (54.1%) | 702 (30.8%) | 1971 (48.3%) | 417 (36.0%) |
| Hypercholesterolemia missing (N, %) | 741 (7.2%) | 28 (3.2%) | 70 (3.6%) | 182 (8.0%) | 333 (8.2%) | 128 (11.1%) |
| Recruitment period | September 2009 – March 2017 | April 2011–May 2013 | September 2009–October 2010 | June 2015–April 2017 | 2009–2010 | February 2011–March 2017 |
| Follow-up time specified in protocol | NA | 30 days | 180 days | 30 days | No follow-up | NA |
NA not available
aStudies were not published